{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:16:40Z","timestamp":1771885000626,"version":"3.50.1"},"reference-count":21,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The sequential and alternating administration of VMP and Rd have equal efficacy and toxicity. The greatest benefit of this total therapy approach was observed for patients aged 65 to 75 years.<\/jats:p>","DOI":"10.1182\/blood-2015-08-666537","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T02:03:34Z","timestamp":1445652214000},"page":"420-425","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":57,"title":["Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM"],"prefix":"10.1182","volume":"127","author":[{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (CAUSA\/IBSAL), Salamanca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Instituto de investigaci\u00f3n 12 de Octubre, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-Teodoro","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique-M.","family":"Ocio","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (CAUSA\/IBSAL), Salamanca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"Hospital Clinic i Provincial, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico San Carlos, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana-Isabel","family":"Teruel","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico de Valencia, Valencia, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma C.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (CAUSA\/IBSAL), Salamanca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Luisa","family":"Mart\u00edn Ramos","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Instituto de investigaci\u00f3n 12 de Octubre, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia, Institut Josep Carreras, Hospital Germans Trials i Pujol, Badalona, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[{"name":"Hospital Son Llatzer, Palma de Mallorca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Bengoechea","sequence":"additional","affiliation":[{"name":"Hospital de Donostia, San Sebastian, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Institut d\u2019Oncologia Dr. Josep Trueta, Girona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"P\u00e9rez de Oteyza","sequence":"additional","affiliation":[{"name":"Hospital de Madrid Sanchinarro, Universidad Centro de Estudios Universitarios San Pablo, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Gironella","sequence":"additional","affiliation":[{"name":"Hospital Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Encinas","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigacion Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Hospital General Virgen del Roc\u00edo, Sevilla, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Hospital San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada (CIMA), Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Instituto de investigaci\u00f3n 12 de Octubre, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noem\u00ed","family":"Puig","sequence":"additional","affiliation":[{"name":"Complejo Asistencial Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (CAUSA\/IBSAL), Salamanca, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"Hospital Clinic i Provincial, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre, Instituto de investigaci\u00f3n 12 de Octubre, Madrid, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada (CIMA), Instituto de Investigaci\u00f3n Sanitaria de Navarra (IDISNA), Pamplona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"18","key":"2019111902550143200_B1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma.","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"2019111902550143200_B2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/asheducation-2013.1.488","article-title":"How should we treat newly diagnosed multiple myeloma patients?","volume":"2013","author":"Mateos","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2019111902550143200_B3","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111902550143200_B4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111902550143200_B5","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","article-title":"Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.","volume":"28","author":"Mateos","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111902550143200_B6","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111902550143200_B7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111902550143200_B8","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111902550143200_B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3390.3390","article-title":"Clinical significance of sensitive flow-MRD monitoring in elderly multiple myeloma patients on the Pethema\/GEM2010MAS65 trial [abstract].","volume":"124","author":"Paiva","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111902550143200_B10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.","volume":"21","author":"Guti\u00e9rrez","year":"2007","journal-title":"Leukemia"},{"issue":"9318","key":"2019111902550143200_B11","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls.","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"2019111902550143200_B12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111902550143200_B13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111902550143200_B14","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111902550143200_B15","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","article-title":"Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.","volume":"120","author":"Mateos","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111902550143200_B16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.81.81","article-title":"Effect of age on efficacy and safety outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) receiving lenalidomide and low-dose dexamethasone (Rd): the first trial [abstract].","volume":"124","author":"Hulin","year":"2014","journal-title":"Blood"},{"key":"2019111902550143200_B17","article-title":"Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single institutional analysis [published online ahead of print August 17, 2015].","author":"Minoia","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2019111902550143200_B18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"issue":"17","key":"2019111902550143200_B19","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111902550143200_B20","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111902550143200_B21","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","article-title":"GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?","volume":"124","author":"Mateos","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/4\/420\/1394800\/420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/4\/420\/1394800\/420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T07:55:10Z","timestamp":1574150110000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/4\/420\/35021\/Sequential-vs-alternating-administration-of-VMP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,28]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-08-666537","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,28]]}}}